An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and the Tolerability of CKD-386(5) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers
Latest Information Update: 07 Nov 2023
At a glance
- Drugs CKD 386 (Primary)
- Indications Dyslipidaemias; Hypertension
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 29 Oct 2023 Status changed from not yet recruiting to completed.
- 31 Jan 2023 New trial record